Ending Australia’s bad drug deal: the three elements of pharmaceutical pricing reform – Grattan Institute – 17 March 2013

Posted on March 18, 2013. Filed under: Health Economics, Pharmacy | Tags: , |

Ending Australia’s bad drug deal: the three elements of pharmaceutical pricing reform – Grattan Institute – 17 March 2013

“Australia’s Pharmaceutical Benefits Scheme pays at least $1.3 billion a year too much for prescription drugs. New Zealand, which has capped its budget and appointed independent experts to make decisions, pays a sixth as much as the PBS for the same drugs. This report proposes three ways Australia can regain its lost leadership in pharmaceutical pricing.”

ABC News report: Government ‘wasting millions’ on prescription drugs – 18 March 2013

Grattan report misses point on PBS reforms – Medicines Australia – 18 March 2013

“Patients would be worse off if Australia adopted a New Zealand-style access to medicines policy, Medicines Australia chief executive Dr Brendan Shaw said today.

Responding to a report on pharmaceutical prices published today by the Grattan Institute, Dr Shaw said proposals to cap spending on the Pharmaceutical Benefits Scheme would limit patient’s access to medicines.

“If you want a how-to guide for turning your health system into that a third-word country, this report would be it,” Dr Shaw said.

“Capping the PBS would kill consumer access to new therapies as the experience in New Zealand proves.

“It undermines the fundamental principal of universal and affordable access to medicines that underpins the Pharmaceutical Benefits Scheme and has done for 60 years.

“Anyone who wants to emulate the New Zealand model of medicines policy should remember that New Zealanders have access to less than half the number of new medicines that Australians have and that New Zealand is stone motherless last in the OECD access to medicines rankings.

“So much so that when New Zealanders can’t access a variety of new medicines in their country they come over here.”

continues on the site

Advertisements
Read Full Post | Make a Comment ( Comments Off on Ending Australia’s bad drug deal: the three elements of pharmaceutical pricing reform – Grattan Institute – 17 March 2013 )

Australian statistics on medicines 2011 – Therapeutic Goods Administration – 17 January 2013

Posted on January 21, 2013. Filed under: Patient Safety, Pharmacy | Tags: , , |

Australian statistics on medicines 2011 – Therapeutic Goods Administration – 17 January 2013

“Australian Statistics on Medicines is produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee (PBAC) and is aimed at providing comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties.

The report from the OPR includes a brief overview on the following aspects of post-market monitoring of medicines in Australia:

•Adverse event reporting statistics for 2011
•Processing and use of adverse event reports
•Reporting adverse events
•Expert advisory committee
•Medicines Safety Update
•Product vigilance”

Read Full Post | Make a Comment ( Comments Off on Australian statistics on medicines 2011 – Therapeutic Goods Administration – 17 January 2013 )

The Impact of PBS Reforms on PBS Expenditure and Savings – Centre for Strategic Economic Studies – 2009

Posted on October 27, 2009. Filed under: Health Economics, Pharmacy | Tags: , |

The Impact of PBS Reforms on PBS Expenditure and Savings: Actual and Projected from 2008-09 to 2017-18
 
Centre for Strategic Economic Studies
 
“This new report by the Centre for Strategic Economic Studies (CSES) at Victoria University examines the impact of PBS reform measures since their implementation.  CSES was commissioned by Medicines Australia to analyse trends in overall PBS expenditure and to report on how recent reforms have affected stakeholders, namely, Government, pharmacists, wholesalers, manufacturers and patients. The report also models the potential impact of the PBS price disclosure mechanism. The findings were reviewed favourably by Access Economics. ”
 
Centre for Strategic Economic Studies (CSES) report  1043k
and organizations currently working in your areas of interest.”

Read Full Post | Make a Comment ( None so far )

Evidence-Based Decision-Making Within Australia’s Pharmaceutical Benefits Scheme – The Commonwealth Fund – 22 July 2009

Posted on July 23, 2009. Filed under: Pharmacy | Tags: , |

R. Lopert, Evidence-Based Decision-Making Within Australia’s Pharmaceutical Benefits Scheme, The Commonwealth Fund, July 2009.

Overview

“In Australia, most prescription drugs are subsidized through the Pharmaceutical Benefits Scheme (PBS), one of several government programs in which evidence-based decision-making is applied to the funding of health technologies. PBS processes are intended to ensure “value for money” for the Australian taxpayer and to support affordable, equitable access to prescription medicines; they are not intended as a mechanism for cost containment. The inclusion of a drug on the national formulary depends on the recommendation of the Pharmaceutical Benefits Advisory Committee (PBAC), which considers not only the comparative effectiveness but also the comparative cost-effectiveness of drugs proposed for listing. While some decisions have been controversial, the PBS retains strong public support. Moreover, evidence does not suggest that the consideration of cost-effectiveness has created a negative environment for the drug industry: Australia has a high penetration of patented medicines, with prices for some recently approved drugs at U.S. levels.”

Read Full Post | Make a Comment ( None so far )

Liked it here?
Why not try sites on the blogroll...